Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- Published In:
- Nature medicine, 28(10), 2083-2091 (2022)
- Authors:
- Garvey, W Timothy(4), Batterham, Rachel L(3), Bhatta, Meena, Buscemi, Silvio, Christensen, Louise N, Frias, Juan P, Jódar, Esteban, Kandler, Kristian, Rigas, Georgia, Wadden, Thomas A, Wharton, Sean
- Database ID:
- RPEP-06130
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06130APA
Garvey, W Timothy; Batterham, Rachel L; Bhatta, Meena; Buscemi, Silvio; Christensen, Louise N; Frias, Juan P; Jódar, Esteban; Kandler, Kristian; Rigas, Georgia; Wadden, Thomas A; Wharton, Sean. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.. Nature medicine, 28(10), 2083-2091. https://doi.org/10.1038/s41591-022-02026-4
MLA
Garvey, W Timothy, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.." Nature medicine, 2022. https://doi.org/10.1038/s41591-022-02026-4
RethinkPeptides
RethinkPeptides Research Database. "Two-year effects of semaglutide in adults with overweight or..." RPEP-06130. Retrieved from https://rethinkpeptides.com/research/garvey-2022-twoyear-effects-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.